Oligomeric HIV-1 Envelope Glycoproteins


This invention embodies a method for generating antibodies to HIV-1 envelope glycoproteins, which could hold powerful implications toward both the diagnosis and the treatment of AIDS. Specifically, the method involves the expression of a soluble protein, gp140, and the generation of antibodies to this protein. gp140 is a recombinant version of gp160, a protein which normally is cleaved in vivo to generate two glycoprotein subunits which are expressed on the surface of the HIV-1 envelope. Unlike previously isolated versions of gp160, gp140 is purified in a manner which preserves the quaternary structural elements of the protein. Due to the conserved nature of these structural elements, antibodies generated against gp140 may be more broadly reactive against various forms of AIDS than other antibodies generated to date.

Inventors:

Patricia Earl (NIAID)  ➽ more inventions...

Christopher Broder (NIAID)  ➽ more inventions...

Robert Doms (NIAID)  ➽ more inventions...

Bernard Moss (NIAID)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 6,039,957 issued 2000-03-21
U.S. Pat: 6,171,596 issued 2001-01-09
US Application No. 08/165,314
US Application No. 09/415,326

Licensing Contact:
Benjamin Hurley, Ph.D.
Email: benjamin.hurley@nih.gov
Phone: 240-669-5092

OTT Reference No: E-200-1993-0
Updated: Sep 16, 2015